All In Biotech

Drug Trial Radar · NCT02503423

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 253 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

253

Actual

Start

Jul 14, 2015

Primary completion

Oct 2022

Study completion Dec 2027

Sponsor

Lead sponsor
Taiho Oncology, Inc.Industry
Sponsor type
Industry
First posted
Jul 21, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target engagement data, in subjects with advanced solid tumors or lymphoma for whom standard life-prolonging measures are not available.

Conditions

  • Solid Tumors
  • Lymphoma

Interventions

  • ASTX660Drug

    described above

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety (Phase 1) - number of subjects with AEs, DLTs, abnormal clinical laboratory values or physical exam resultsTime frame: Up to 78 months
  2. Efficacy (Phase 2) - antitumor activity assessed by objective response rate (ORR)Time frame: Up to 84 months
  3. Efficacy (Phase 2) - antitumor activity assessed by disease control rate (DCR)Time frame: Up to 84 months

Locations

68 sites in 8 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • UC Davis Medical Center

    Sacramento, California

  • Simlow Cancer Hospital at Yale

    New Haven, Connecticut

  • Emory University winship Cancer Institute

    Atlanta, Georgia

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Chicago, Illinois

  • The Sidney Kimmel Comprehensive Cancer Center at John Hopkins

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Dartmouth-Hitchcock Medical Center (DHMC)

    Lebanon, New Hampshire

  • Summit Medical Group - Florham Park Campus/Atlantic Health

    Florham Park, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • New York University Langone Medical Center

    New York, New York

  • New York Presbyterian Hospital Columbia University Medical Center

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Rochester Skin Lymphoma Medical Group

    Rochester, New York

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina

  • The Ohio State University and Wexner Medical Center, James Cancer Hospital

    Columbus, Ohio

  • University of Oklahoma Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Oregon Health and Science University

    Portland, Oregon

  • West Penn Hospital

    Pittsburgh, Pennsylvania

  • Hollings Cancer Center

    Charleston, South Carolina

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • CliniCore Texas

    Houston, Texas

  • START- South Texas Accelerated Research Therapeutics

    San Antonio, Texas

  • Virgina Commonwealth University

    Richmond, Virginia

  • University of Washington, Seattle Cancer Care Alliance

    Seattle, Washington

  • Intitut Jules Boredt

    Brussels, Belgium

  • Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne

    Yvoir, Namur, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Oost-Vlaanderen, Belgium

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • British Columbia Cancer Agency

    Vancouver, British Columbia, Canada

  • Cancer Care Manitoba

    Winnipeg, Manitoba, Canada

  • Nova Scotia Health Athority-Qeii HSC

    Halifax, Nova Scotia, Canada

  • Sunnybrook Hospital

    Toronto, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.